Comments on the 2018 European Thyroid Association Guidelines for the management of amiodarone-associated thyroid dysfunction

Main Article Content

Yu.V. Buldyhina
H.М. Terekhova
V.I. Pankiv


In this article, the authors described and commented the main provisions of the new guidelines for the examination and treatment of patients with amiodarone-associated thyroid dysfunction. Their text is divided thematically into subdivisions (clinical studies, diagnosis, approaches to the management). At the same time, the text with references is presented first that followed by guidelines, which are given according to the level of evidence.

Article Details

How to Cite
Buldyhina, Y., H. Terekhova, and V. Pankiv. “Comments on the 2018 European Thyroid Association Guidelines for the Management of Amiodarone-Associated Thyroid Dysfunction”. INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine), vol. 14, no. 3, Apr. 2018, pp. 251-62, doi:10.22141/2224-0721.14.3.2018.136423.
Methodical Recomendations


Bogazzi F, Bartalena L, Martino E. Approach to the patient with amiodarone-induced thyrotoxicosis. J Clin Endocrinol Metab. 2010 Jun;95(6):2529-35. doi: 10.1210/jc.2010-0180.

Martino E, Bartalena L, Bogazzi F, Braverman LE. The effects of amiodarone on the thyroid. Endocr Rev. 2001 Apr;22(2):240-54. doi: 10.1210/edrv.22.2.0427.

Tanda ML, Piantanida E, Lai A, et al. Diagnosis and management of amiodarone-induced thyrotoxicosis: similarities and differences between North American and European thyroidologists. Clin Endocrinol (Oxf). 2008 Nov;69(5):812-8. doi: 10.1111/j.1365-2265.2008.03268.x.

Raghavan RP, Taylor PN, Bhake R, et al. Amiodarone-induced thyrotoxicosis: an overview of UK management. Clin Endocrinol (Oxf). 2012 Dec;77(6):936-7. doi: 10.1111/j.1365-2265.2012.04435.x.

Ahmed S, Van Gelder IC, Wiesfeld ACP, Van Veldhuisen DJ, Links TP. Determinants and outcome of amiodarone-associated thyroid dysfunction. Clin Endocrinol (Oxf). 2011 Sep;75(3):388-94. doi: 10.1111/j.1365-2265.2011.04087.x.

Trip MD, Wiersinga W, Plomp TA. Incidence, predictability, and pathogenesis of amiodarone-induced thyrotoxicosis and hypothyroidism. Am J Med. 1991 Nov;91(5):507-11.

Swiglo BA, Murad MH, Schunemann HJ, et al. A case for clarity, consistency and helpfulness: State-of-the-art clinical practice guidelines in endocrinology using the grading of recommendations, assessment, development, and evaluation system. J Clin Endocrinol Metab. 2008 Mar;93(3):666-73. doi: 10.1210/jc.2007-1907.

Lambert MJ, Burger AG, Galeazzi RL, Engler D. Are selective increases in serum thyroxine (T4) due to iodinated inhibitors of T4 monodeiodination indicative of hyperthyroidism? J Clin Endocrinol Metab. 1982 Dec;55(6):1058-65. doi: 10.1210/jcem-55-6-1058.

Nademanee K, Singh BN, Callahan B, Hendrickson JA, Hershman JM. Amiodarone, thyroid indexes, and altered thyroid function: long-term serial effects in patients with cardiac arrhythmias. Am J Cardiol. 1986 Nov 1;58(10):981-6.

Franklyn JA, Davis JR, Gammage MD, Littler WA, Ramsden DB, Sheppard MC. Amiodarone and thyroid hormone action. Clin Endocrinol (Oxf). 1985 Mar;22(3):257-64.

Yamazaki K, Mitsuhashi T, Yamada E, et al. Amiodarone reversibly decreases sodium-iodide symporter mRNA expression at therapeutic concentrations and induces antioxidant responses at supraphysiological concentrations in cultured human thyroid follicles. Thyroid. 2007 Dec;17(12):1189-200. doi: 10.1089/thy.2007.0215.

Melmed S, Nademanee K, Reed AW, Hendrickson JA, Singh BN, Hershman JM. Hyperthyroxinemia with bradycardia and normal thyrotropin secretion after chronic amiodarone administration. J Clin Endocrinol Metab. 1981 Nov;53(5):997-1001. doi: 10.1210/jcem-53-5-997.

Hershman JM, Nademanee K, Sugawara M, et al. Thyroxine and triiodothyronine kinetics in cardiac patients taking amiodarone. Acta Endocrinol (Copenh). 1986 Feb;111(2):193-9.

Amico JA, Richardson V, Alpert B, Klein I. Clinical and chemical assessment of thyroid function during therapy with amiodarone. Arch Intern Med. 1984 Mar;144(3):487-90.

Unger J, Lambert M, Jonckheer MH, Denayer P. Amiodarone and the thyroid: pharmacological, toxic and therapeutic effects. J Intern Med. 1993 Jun;233(6):435-43.

Wiersinga WM, Trip MD. Amiodarone and thyroid hormone metabolism. Postgrad Med J. 1986 Oct;62(732):909-14.

Batcher EL, Tang XC, Singh BN, Singh SN, Reda DJ, Hershman JM; SAFE-T Investigatorsю Thyroid function abnormalities during amiodarone therapy for persistent atrial fibrillation. Am J Med. 2007 Oct;120(10):880-5. doi: 10.1016/j.amjmed.2007.04.022.

Zhong B, Wang Y, Zhang G, Wang Z. Environmental iodine content, female sex and age are associated with new-onset amiodarone-induced hypothyroidism: a systematic review and meta-analysis of adverse reactions of amiodarone on the thyroid. Cardiology. 2016;134(3):366-71. doi: 10.1159/000444578.

Bogazzi F, Tomisti L, Bartalena L, Aghini-Lombardi F, Martino E. Amiodarone and the thyroid: a 2012 update. J Endocrinol Invest. 2012 Mar;35(3):340-8. doi: 10.3275/8298.

Harjai K, Licata A: Effects of Amiodarone on thyroid function. Ann Intern Med. 1997 Jan 1;126(1):63-73.

Stott DJ, Rodondi N, Kearney PM, et al. Thyroid hormone therapy for older adults with subclinical hypothyroidism. N Engl J Med. 2017 Jun 29;376(26):2534-2544. doi: 10.1056/NEJMoa1603825.

Benjamens S, Dullaart RPF, Sluiter WJ, Rienstra M, van Gelder IC, Links TP. The clinical value of regular thyroid function tests during amiodarone treatment. Eur J Endocrinol. 2017 Jul;177(1):9-14. doi: 10.1530/EJE-17-0018.

Bartalena L, Bogazzi F, Braverman LE, Martino E. Effects of amiodarone administration during pregnancy on neonatal thyroid function and subsequent neurodevelopment. J Endocrinol Invest. 2001 Feb;24(2):116-30. doi: 10.1007/BF03343825.

Theodoraki A, Vanderpump MPJ. Thyrotoxicosis associated with the use of amiodarone: the utility of ultrasound in patient management. Clin Endocrinol (Oxf). 2016; 84(2):172-176. doi: 10.1111/cen.12988.

Bogazzi F, Bartalena L, Dell’Unto E, et al. Proportion of type 1 and type 2 amiodarone-induced thyrotoxicosis has changed over a 27-year period in Italy. Clin Endocrinol (Oxf). 2007 Oct;67(4):533-7. doi: 10.1111/j.1365-2265.2007.02920.x.

Balzano S, Sau F, Bartalena L, et al. Diagnosis of amiodarone-iodine-induced thyrotoxicosis (AIIT) associated with severe nonthyroidal illness. Clin Endocrinol (Oxf). 2007 Oct;67(4):533-7. doi: 10.1111/j.1365-2265.2007.02920.x.

Tomisti L, Urbani C, Rossi G, et al. The presence of anti-thyroglobulin (TgAb) and/or anti-thyroperoxidase antibodies (TPOAb) does not exclude the diagnosis of type 2 amiodarone-induced thyrotoxicosis. J Endocrinol Invest. 2016 May;39(5):585-91. doi: 10.1007/s40618-015-0426-0.

Piga M, Cocco MC, Serra A, Boi F, Loy M, Mariotti S. The usefulness of 99mTc-sestaMIBI thyroid scan in the differential diagnosis and management of amiodarone-induced thyrotoxicosis. Eur J Endocrinol. 2008 Oct;159(4):423-9. doi: 10.1530/EJE-08-0348.

Pattison DA, Westcott J, Lichtenstein M, et al. Quantitative assessment of thyroid-to-background ratio improves the interobserver reliability of technetium-99m sestamibi thyroid scintigraphy for investigation of amiodarone-induced thyrotoxicosis. Nucl Med Commun. 2015 Apr;36(4):356-62. doi: 10.1097/MNM.0000000000000260.

Loy M, Perra E, Melis A, et al. Color-flow Doppler sonography in the differential diagnosis and management of amiodarone-induced thyrotoxicosis. Acta Radiol. 2007 Jul;48(6):628-34. doi: 10.1080/02841850701342138.

Yiu KH, Jim MH, Siu CW, et al. Amiodarone-induced thyrotoxicosis is a predictor of adverse cardiovascular outcome. J Clin Endocrinol Metab. 2009 Jan;94(1):109-14. doi: 10.1210/jc.2008-1907.

O’Sullivan AJ, Lewis M, Diamond T. Amiodarone-induced thyrotoxicosis: left ventricular dysfunction is associated with increased mortality. Eur J Endocrinol. 2006 Apr;154(4):533-6. doi: 10.1530/eje.1.02122.

Wang TJ, Evans JC, Benjamin EJ, Levy D, LeRoy EC, Vasan RS. Natural history of asymptomatic left ventricular systolic dysfunction in the community. Circulation. 2003 Aug 26;108(8):977-82. doi: 10.1161/01.CIR.0000085166.44904.79.

Tomisti L, Del Re M, Bartalena L, et al. Effects of amiodarone, thyroid hormones and CYP2C9 and VKORC1 polymorphisms on warfarin metabolism: a review of the literature. Endocr Pract. 2013 Nov-Dec;19(6):1043-9. doi: 10.4158/EP13093.RA.

Tomisti L, Materazzi G, Bartalena L, et al. Total thyroidectomy in patients with amiodarone-induced thyrotoxicosis and severe left ventricular systolic dysfunction. J Clin Endocrinol Metab. 2012 Oct;97(10):3515-21. doi: 10.1210/jc.2012-1797.

Pierret C, Tourtier JP, Pons Y, Merat S, Duverger V, Perrier E. Total thyroidectomy for amiodarone-associated thyrotoxicosis: should surgery always be delayed for pre-operative medical preparation? J Laryngol Otol. 2012 Jul;126(7):701-5. doi: 10.1017/S0022215112000722.

Kaderli RM, Fahrner R, Christ ER, et al. Total thyroidectomy for amiodarone-induced thyrotoxicosis in the hyperthyroid state. Exp Clin Endocrinol Diabetes. 2016 Jan;124(1):45-8. doi: 10.1055/s-0035-1565094.

Zhu L, Zainudin SB, Kaushik M, Khor LY, Chng CL. Plasma exchange in the treatment of thyroid storm secondary to type II amiodarone-induced thyrotoxicosis. Endocrinol Diabetes Metab Case Rep. 2016;2016:160039. doi: 10.1530/EDM-16-0039.

Eskes SA, Endert E, Fliers E, et al. Treatment of amiodarone-induced thyrotoxicosis type 2: a randomized clinical trial. J Clin Endocrinol Metab. 2012 Feb;97(2):499-506. doi: 10.1210/jc.2011-2390.

Uzan L, Guignat L, Meune C, et al. Continuation of amiodarone therapy despite type II amiodarone-induced thyrotoxicosis. Drug Saf. 2006;29(3):231-6.

Sato K, Shiga T, Matsuda N, Onoda N, Takano K, Hagiara N, Kasanuki H. Mild and short recurrence of type II amiodarone-induced thyrotoxicosis in three patients receiving amiodarone continuously for more than 10 years. Endocr J. 2006 Aug;53(4):531-8.

Bogazzi F, Bartalena L, Tomisti L, Rossi G, Brogioni S, Martino E. Continuation of amiodarone delays restoration of euthyroidism in patients with type 2 amiodarone-induced thyrotoxicosis treated with prednisone: a pilot study . J Clin Endocrinol Metab. 2011 Nov;96(11):3374-80. doi: 10.1210/jc.2011-1678.

Eskes SA, Wiersinga WM. Amiodarone and thyroid. Best Pract Res Clin Endocrinol Metab. 2009 Dec;23(6):735-51. doi: 10.1016/j.beem.2009.07.001.

Jabrocka-Hybel A, Bednarczuk T, Bartalena L, Pach D, et al. Endokrynol Pol. 2015;66(2):176-86. doi: 10.5603/EP.2015.0025.

Bogazzi F, Tomisti L, Rossi G, et al. Glucocorticoids are preferable to thionamides as first-line treatment for amiodarone-induced thyrotoxicosis due to destructive thyroiditis: a matched retrospective cohort study. J Clin Endocrinol Metab. 2009 Oct;94(10):3757-62. doi: 10.1210/jc.2009-0940.

Bogazzi F, Bartalena L, Cosci C, et al. Treatment of type II amiodarone-induced thyrotoxicosis by either iopanoic acid or glucocorticoids: a prospective, randomized study. J Clin Endocrinol Metab. 2003 May;88(5):1999-2002. doi: 10.1210/jc.2002-021874.

Dickstein G, Shechner C, Adawi F, Kaplan J, Baron E, Ish-Shalom S. Lithium treatment in amiodarone-induced thyrotoxicosis. Am J Med. 1997 May;102(5):454-8. doi: 10.1016/S0002-9343(97)00047-8.

Han TS, Williams GR, Vanderpump MPJ. Benzofuran derivatives and the thyroid. Clin Endocrinol (Oxf). 2009 Jan;70(1):2-13. doi: 10.1111/j.1365-2265.2008.03350.x.

Bogazzi F, Bartalena L, Tomisti L, et al. Glucocorticoid response in amiodarone-induced thyrotoxicosis resulting from destructive thyroiditis is predicted by thyroid volume and serum free thyroid hormone concentrations. J Clin Endocrinol Metab. 2007 Feb;92(2):556-62. doi: 10.1210/jc.2006-2059.

Vanderpump MP. Thyroid gland: use of glucocorticoids in amiodarone-induced thyrotoxicosis. Nat Rev Endocrinol. 2009 Dec;5(12):650-1. doi: 10.1038/nrendo.2009.218.

Albino CC, Paz-G, Graf H. Recombinant human TSH as an adjuvant to radioiodine for the treatment of type 1 amiodarone-induced thyrotoxicosis (AIT). Clin Endocrinol (Oxf). 2009 May;70(5):810-1. doi: 10.1111/j.1365-2265.2008.03405.x.

Bogazzi F, Tomisti L, Ceccarelli C, Martino E. Recombinant human TSH as an adjuvant to radioiodine for the treatment of type 1 amiodarone-induced thyrotoxicosis: a cautionary note. Clin Endocrinol (Oxf). 2010 Jan;72(1):133-4. doi: 10.1111/j.1365-2265.2009.03600.x.

Houghton SG, Farley DR, Brennan MD, van Heerden JA, Thompson GB, Grant CS. Surgical management of amiodarone-associated thyrotoxicosis: Mayo Clinic experience. World J Surg. 2004 Nov;28(11):1083-7. doi: 10.1007/s00268-004-7599-6.

Gough J, Gough IR. Total thyroidectomy for amiodarone-associated thyrotoxicosis in patients with severe cardiac disease. World J Surg. 2006 Nov;30(11):1957-61. doi: 10.1007/s00268-005-0673-x.

Maqdasy S, Batisse-Lignier M, Auclair C, et al. Amiodarone-induced thyrotoxicosis recurrence after amiodarone reintroduction. Am J Cardiol. 2016 Apr 1;117(7):1112-6. doi: 10.1016/j.amjcard.2016.01.003.

Ryan LE, Braver

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 9 10 11 12 > >>